| 摘要: |
| 目的 研究复合乳酸菌肠溶胶囊(LCC)增强肾衰宁胶囊(SSN)对输尿管梗阻(UUO)手术大鼠模型肾纤维化的保护作用。方法 测定复合乳酸菌肠溶胶囊(LCC)中乳酸菌含量,输尿管梗阻(UUO)手术建立大鼠肾纤维化模型并每天灌胃给药,21天后记录终末体重并计算肾系数;生化仪检测BUN,Scr和MAU的变化;病理切片HE染色和masson染色观察肾脏的组织形态及纤维化程度;免疫组织化学法检测肾组织中α-SMA和Col1A等蛋白表达;ELISA法检测肾组织中IL-6、TNF-α、CRP和TGF-β含量及血清中D-乳酸、内毒素和二胺氧化酶( DAO)含量;Q-PCR法检测回肠组织中ZO-1、Occludin、Claudin-1和Claudin-2的mRNA表达。结果 LCC联合SSN治疗可显著降低UUO肾纤维化大鼠的肾系数,BUN,Scr以及MAU的水平,大鼠体重也显著升高;明显改善肾脏组织形态及胶原蓄积;降低α-SMA和Col1A蛋白表达,IL-6、TNF-α、CRP、TGF-β、D-乳酸和二胺氧化酶( DAO)含量;升高ZO-1、Occludin、Claudin-1的mRNA表达并降低Claudin-2的mRNA表达,最终起到改善肾纤维化的作用。结论 复合乳酸菌肠溶胶囊(LCC)可增强肾衰宁胶囊(SSN)对肾纤维化的改善作用,其作用主要与抗炎、抗纤维化、调节菌群平衡及改善肠黏膜屏障有关,依据肾-肠轴理论,为治疗肾纤维化提供了依据和新的治疗方法。 |
| 关键词: 复合乳酸菌肠溶胶囊 肾衰宁胶囊 肾纤维化 |
| DOI:10.13506/j.cnki.jpr.2024.02.004 |
| 基金项目:江苏省市场监督管理局科技计划项目(No.KJ21125094) |
|
|
|
| Study of the protective effect of Lactic acid bacteria Complex Enteric Capsules strengthen Shenshuaining Capsules on renal fibrosis |
| YANG Hao1,SONG Xianrui2,ZHANG Lei1 |
| (1.Jiangsu Institute for Food and Drug Control, Nanjing 210019,China;2.Nanjing University of Chinese Medicine,Nanjing 210000,China) |
| Abstract: |
| Objective To investigate the protective effect of Lactic acid bacteria Complex Enteric Capsules (LCC) combined with Shenshuaining Capsules (SSN) on renal fibrosis in the ureteral obstruction (UUO) surgical rat models.Methods Lactic acid bacteria Complex Enteric Capsules (LCC) were tested. The UUO surgery was performed to establish renal fibrosis model in rat models. After drug combination of LCC and SSN for 21 days, terminal body weight was recorded and the renal coefficient was calculated; BUN、Scr and MAU was detected by biochemical instrument; Kidney tissue morphology and the degree of fibrosis were observed and evaluated by HE and masson staining; the expression of α -SMA and Col 1 A in kidney tissues was determined by immunohistochemistry; the content of IL-6, TNF- α, CRP and TGF- β in renal tissue and the content of D-lactate, endotoxin and diamine oxidase (DAO) in serum were detected by ELISA; the mRNA expression of ZO-1, Occludin, Claudin-1, and Claudin-2 in the ileal tissue was determined by Q-PCR.Results Compared to SSN group, the rat models with drug combination of LCC combined with SSN treatment significantly reduced renal coefficient, BUN, Scr and MAU; increased the body weight; significantly improved renal tissue morphology and collagen accumulation; decreased the expression of α -SMA and Col 1 A protein, IL-6, TNF-α, CRP, TGF-β, D-lactate and diamine oxidase (DAO); increased mRNA expression of ZO-1, Occludin, Claudin-1 and decreased mRNA expression of Claudin-2, and ultimately improved renal fibrosis.Conclusion Compound Lactic acid bacteria Complex Enteric Capsules (LCC) can enhance the improvement of Shenshuaining Capsules (SSN) on renal fibrosis, and its effect is mainly related to anti-inflammation, anti-fibrosis, regulation of microflora balance and improvement of intestinal mucosal barrier. Based onthe renal-intestinal axis theory, it provides a basis and a new treatment method for the treatment of renal fibrosis. |
| Key words: Lactic acid bacteria Complex Enteric Capsules Shenshuaining Capsules Renal fibrosis |